Connect to other sites within the UBM Medica Network
MRI Screening for Breast Cancer
As part of our MBCC coverage we discuss MRI screening for breast cancer in patients who carry a BRCA mutation or have a first-degree relative who is a BRCA carrier.
Pain Control an Important Aspect of Breast Cancer Treatment
As part of our MBCC coverage, we discuss how physicians can improve the patient experience through pain control both during and after breast cancer treatment.
Hormone Therapy Adherence in Breast Cancer Linked to Race, Income
Economic factors, including household income, and racial disparities both play a role in the adherence to hormonal therapy in breast cancer patients.
Unlikelihood of Cure Did Not Reduce Chemo Use at End of Life
Patients with lung and colorectal cancer who understood that chemotherapy would not cure them were no less likely to receive chemotherapy at the end of life.
Phone Counseling Improves QOL in Cervical Cancer Survivors
Cervical cancer survivors saw improvements in self-reported quality-of-life outcomes with a psychosocial telephone counseling intervention, according to a new study.
Higher-Risk Prostate Cancer on the Rise?
A large retrospective analysis suggests the number of patients diagnosed with intermediate- and high-risk prostate cancer has increased since 2011.
Order of Gene Mutations May Affect Outcomes in Myeloproliferative Neoplasms
New data indicates that the order in which people acquired certain somatic mutations influenced several clinical features of myeloproliferative neoplasms.
Increased Risk of Aggressive Prostate Cancer in Testicular Cancer Survivors
Patients with a history of testicular cancer had a fivefold higher risk of developing aggressive prostate cancer when compared with those with no history of testicular cancer.
AR-V7 Biomarker Could Guide Treatment in mCRPC Patients
Levels of AR-V7 in metastatic castration-resistant prostate cancer patients could guide physicians to treat with either taxanes or enzalutamide/abiraterone.
FDA Approves Front-Line Lenalidomide for Multiple Myeloma
The FDA has expanded the use of oral lenalidomide in multiple myeloma to include its use in combination with dexamethasone for newly diagnosed patients.
By clicking Accept, you agree to become a member of the UBM Medica Community.